Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779126 | 0.87 | RXFP1 (0.48) | BUB1ALDH1A1KDM4ELMNARXFP1 | |
| SCHEMBL6767875 | 0.87 | ALDH1A1 (0.53) | ALDH1A1RXFP1HTTTP53THRB | |
| SCHEMBL5733437 | 0.86 | NHERF1 (0.49) | BUB1ALDH1A1RXFP1HTTTP53 | |
| SCHEMBL6774119 | 0.86 | EHMT2 (0.51) | BUB1ALDH1A1KDM4ERXFP1POLB | |
| SCHEMBL6770340 | 0.84 | BUB1 (0.40) | BUB1ALDH1A1LMNARXFP1TP53 | |
| SCHEMBL7395661 | 0.83 | ROCK2 (0.57) | HPGDALDH1A1KDM4ELMNARXFP1 | |
| SCHEMBL6772558 | 0.82 | MAPT (0.48) | ALDH1A1RXFP1POLBHTTTP53 | |
| SCHEMBL6772359 | 0.82 | POLB (0.49) | HPGDALDH1A1RXFP1POLBHTT | |
| SCHEMBL7361057 | 0.82 | POLB (0.46) | BUB1HPGDALDH1A1RXFP1POLB | |
| SCHEMBL7361612 | 0.82 | POLB (0.46) | BUB1HPGDKDM4ERXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | claimed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | claimed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | claimed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | claimed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1998002420-A9 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | — | 1998-04-23 | — | — | WO | claimed |
| EP-0825193-A1 | Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1998002420-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-22 | — | — | WO | claimed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | claimed |
| US-6720339-B2 | SUCH AS N-PHENYL-4-OXO-6,6-DIMETHYL-4,5,6,7-TETRAHYDRO-1H-INDOLE-3-CARBOXAMIDE; FOR DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR MEMORY ENHANCEMENT | NEUROGEN CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2002-12-26 | — | — | US | disclosed |
| US-6353109-B2 | PSYCHOLOGICAL DISORDERS; SLEEP DISORDERS; ANTICONVULSANTS; COGNITION ACTIVATORS | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | ALBAUGH PAMELA (US) | 2001-09-06 | — | — | US | disclosed |
| US-5925770-A | GAMMA-AMINOBUTYRIC ACID DERIVATIVES FOR DIAGNOSIS OR TREATMENT OF ANXIETY, SLEEP DISORDERS, SEIZURES, OVERDOSES OF BENZODIAZEPINE TYPE DRUGS, COGNITION ACTIVATORS | NEUROGEN CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0888300-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5750702-A | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1998002420-A9 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | — | 1998-04-23 | — | — | WO | disclosed |
| EP-0825193-A1 | Certain fused pyrrolecarboxanilides; a new class of gaba brain receptor ligands | NEUROGEN CORPORATION (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1998002420-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997034870-A1 | CERTAIN FUSED PYRROLECARBOXAMIDES AS GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020035-A1 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators | GABRA1, GABRA4, GABRA2 | BUB1 1452/4885HPGD 1539/4885ALDH1A1 1550/4885 |
| US-20020198204-A1 | Such as n-phenyl-4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxamide; for diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs, and for memory enhancement | CNR1, HTR1A, GABRA6 | BUB1 2217/4885HPGD 1116/4885ALDH1A1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.